Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Pharmaceutical laboratories have been adopting imm
Bullet ants (Paraponera clavata) are famous for ha
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
CureVac’s experimental COVID-19 vaccine triggered an immune response in humans, it said on Monday, placing the German biotech firm on track to start mass testing this year since the race to end the pandemic heats up.
“We are very encouraged by the interim Phase I data,” Chief Executive Officer Franz-Werner Haas said in a statement,
The biotech firm is using the so-called messenger RNA (mRNA) approach, the same as Moderna in addition to BioNTech and its partner Pfizer, although they began mass testing on humans in late July.
CureVac said its possible vaccine, called CVnCoV, was generally well tolerated and results strongly supported the corporation’s plans to establish the final stage of testing on humans before the end of the year.CureVac – backed by German biotech investor Dietmar Hopp, the Gates Foundation and GlaxoSmithKline – stated volunteers developed a level of neutralising antibodies on par with people who had recovered from a severe case of COVID-19.
The pandemic, which has claimed over 1.1 million lives globally, has triggered a scramble to develop a vaccine with about 45 experimental chemicals being tested on humans.
Britain’s AstraZeneca, working with the University of Oxford, is also among leading contenders with late-stage trial results expected this season but their candidate relies on another virus, rather than mRNA, to deliver genetic instructions to the body for an immunisation effect.
Anthony Fauci, the top US infectious diseases expert, said on Thursday that the first doses of a safe and efficient coronavirus vaccine will probably become available to some high-risk Americans in late December or early January.
CureVac’s hopes of supplying a vaccine at much lower doses than its mRNA competitors may have been dented as it’s picked the maximum concentration of five doses – from 2 to 12 microgrammes per shot – for its prospective Phase III trial.
BioNTech and Pfizer have stated the 30 microgramme shot they opted for in their late-stage trial had previously been demonstrated to produce antibody levels above those registered in people who recovered from COVID-19.
Moderna, which like BioNTech expects to have first efficacy data from its mass trial this month, is testing a 100 microgramme shot which has been shown to trigger an antibody response above that of recovered patients.
CureVac, which went public on the Nasdaq market in August, stated its Phase I study has so far enrolled more than 250 healthy individuals aged 18 to 60 years in Germany and Belgium.
It said its inoculation appears to also generate T cells from the coronavirus, another key indicator of a successful immune system arsenal, but more analysis of the was ongoing.
It said side effects occurred mostly after the second injection of its two-dose regimen and included fatigue, headache, chills, muscle pain and, to a lesser extent, fever.
These conditions”resolved rapidly, usually within 24 to 48 hours”, it stated.
